- Mallinckrodt to present five clinical studies on TERLIVAZ® (terlipressin) at Digestive Disease Week 2025.
- Research focuses on treating hepatorenal syndrome with rapid kidney function reduction.
- Study highlights include real-world outcomes and safety concerns.
Mallinckrodt plc has announced its upcoming presentation of five clinical studies on TERLIVAZ® (terlipressin) during the Digestive Disease Week (DDW) 2025 in San Diego. The studies will focus on the treatment of hepatorenal syndrome (HRS) characterized by a rapid reduction in kidney function, also known as HRS-acute kidney injury (AKI).
TERLIVAZ is currently the only FDA-approved medication for this rare and serious condition, affecting over 42,000 Americans annually, or approximately 0.01% of the U.S. population. The presentations, taking place from May 3-6, 2025, will include one oral presentation and four poster sessions, covering areas such as real-world treatment outcomes, comparative analyses between patients in the UK and the US, and efficacy in patients with alcohol-associated liver disease.
Key highlights of the presentations include research on transplant waitlist status and treatment benefit-to-risk profiles. It's important to note that TERLIVAZ may pose serious safety concerns, including the risk of respiratory failure, particularly in patients with volume overload or Grade 3 acute-on-chronic liver failure. Continuous monitoring of oxygenation levels is recommended during treatment.
The presentations aim to provide a deeper understanding of TERLIVAZ's efficacy and safety in real-world settings, with the potential to improve patient outcomes in those suffering from HRS-AKI. The event promises to be a significant platform for discussing advancements in digestive disease treatment among global healthcare professionals and researchers.
